| 000 | 01663 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514033447.0 | ||
| 264 | 0 | _c20021125 | |
| 008 | 200211s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1046/j.1365-2036.2002.01273.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSabate, J M | |
| 245 | 0 | 0 |
_aAn open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cJun 2002 |
||
| 300 |
_a1117-24 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aCrohn Disease _xcomplications |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFistula _xdrug therapy |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aThalidomide _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aVillarejo, J | |
| 700 | 1 | _aLemann, M | |
| 700 | 1 | _aBonnet, J | |
| 700 | 1 | _aAllez, M | |
| 700 | 1 | _aModigliani, R | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 16 _gno. 6 _gp. 1117-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2036.2002.01273.x _zAvailable from publisher's website |
| 999 |
_c11928388 _d11928388 |
||